Clinical Trial Update: MSCs for Prevention of MI-induced HF [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating mesenchymal stem cells to prevent heart failure after myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Shiraz University of Medical Sciences | Conditions: Myocardial Infarction, Acute, Myocardial Infarction First | Phase 3 | Status: COMPLETED